BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

LUND, SE / ACCESSWIRE / November 3, 2023 / BioInvent International (STO:BINV):Preliminary data from Phase 1 part show encouraging early efficacy signalsRobust partial response in one patient with gastrointestinal tumor; 7 cases of stable …